Read May eNews here 👉 https://shorturl.at/4OR54 Featuring: ✅ Connecting for Success,  by Tony Jones, CEO, One Nucleus✅ Creating the Home of Champions by Tony Jones, CEO, One Nucleus✅ An Adventurous Biotech CEO on Priya Mande, CEO of RNAvate✅ Covalent Drug Discovery: Challenges, Advances, and Success Stories by Domainex✅ Venture Capital Term Sheet Guide 2025 by HSBC✅ Drug Discovery Goes Multimodal: The Evolving Design Continuum by Arctoris✅ Meet Your Next Business Partner at the #ONHelix25 Conference

Spark Therapeutics veteran brings over 25 years’ of leadership experience to drive translation of company’s bicistronic gene therapies into products. Ikarovec, which is developing field-changing bicistronic gene therapies for ophthalmic diseases, appoints Dr Thomas Ciulla, expert in ophthalmology drug development, as President and CEO. Dr Ciulla directed medical strategy for Luxturna, the first FDA-approved gene therapy for inherited retinal disease, at Spark Therapeutics, with other development achievements at Viridian Therapeutics, Iveric Bio and Clearside Biomedical. Dr Ciulla will drive…

– Camgenium and Cardiac Tech have developed an innovative solution to adverse events caused by current temporary pacing methods used in intensive care wards – – Pace-Protect will be the first medical device using a Soft Silicon™ mesh network to be deployed in a clinical environment – Camgenium, a leading medical software engineering company, announced further details of its partnership with MedTech innovator Cardiac Tech to develop and deploy their new medical device product, Pace-Protect. This pioneering medical device has the potential to significantly improve patient outcomes following…

Discovery Park is announcing the retirement of Dr. Martino Picardo, esteemed Chairman. During his seven-year tenure at Discovery Park, Martino’s leadership drove transformative growth, with the Kent science and tech hub recognised as a Life Sciences Opportunity Zone and home to over 180 companies. Over a career spanning more than 30 years, Martino has continually championed the potential of the life sciences sector and the importance of building an environment for innovation to flourish. As Chairman, Martino played a key role in strengthening Discovery Park’s position as a leading destination…

RxCelerate, the Cambridge-based out-sourced drug discovery and development leader, has unveiled a world-class Scientific Advisory Board (SAB) for its rapidly growing antibody discovery group, RxBiologics. The SAB will be chaired by RxBiologics co-founder and world-renowned antibody engineer Jonny Finlay.  Jonny was responsible for the initial design of the Galaxy® display library platform that RxBiologics launched in February 2021, which incorporates the world’s first in-line optimisation technology that mimics the way B cells generate high affinity and specificity antibodies in vivo.  As a…

Data presented at AACR Annual Meeting in Chicago Cambridge, UK – 29 April 2025: Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), has presented new data on the mechanism of action of MB097 at the American Association for Cancer Research (AACR) annual meeting held in Chicago, April 25-30. MB097 is an LBP in development as a co-therapy for immune checkpoint inhibitors (CPI) such as MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). The composition of…

Validated drug discovery assay overcomes previous challenges in targeting NaV1.9 ion channels for chronic pain signalling Completes unique suite of rapid, scalable pain-related sodium channel assays and services to accelerate hit-to-lead and lead optimisation programmes Cambridge, UK, 28 April 2025: Metrion Biosciences (“Metrion”), the specialist preclinical contract research organisation (CRO) and a global leader in ion channel services, today announced the launch of its validated, high-throughput NaV1.9 screening assay to advance discovery and development of novel pain therapeutics.…

Pioneer Group, leading developer of life science ecosystems, integrating infrastructure, investment, and venture support, and ZEISS, a global leader in optical and optoelectronic technology, have unveiled a strategic partnership. Through the partnership, which kicks off at Victoria House in London, but is set to expand across the wider Pioneer network, ZEISS will empower tenant researchers with advanced imaging technology for biotech and pharmaceutical innovations, help to foster a collaborative ecosystem that enables startups and research groups to leverage ZEISS expertise and technology,…

The April edition of our People Pathways newsletter is available to read here! Featuring: ✅ One Nucleus upcoming courses✅ Blog including key takeaways from the 31 March skills roundtable✅ Cyber awareness survey✅ UCL Summer Courses

Partnership to validate and promote the application of CN Bio’s PhysioMimix technology, with future opportunities for novel application and assay development Cambridge, UK, 24 April 2025: CN Bio, a leading provider of Organ-on-a-chip systems and solutions that accelerate drug discovery and development workflows, today announced the establishment of a strategic partnership with Pharmaron, a premier R&D service provider for the life sciences industry. Under the agreement, Pharmaron will validate CN Bio’s PhysioMimix® technologyacross existing applications and collaborate…